ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 179

Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome

Amanda K. Ombrello1, Patrycja M. Hoffmann1, Anne Jones1, Karyl Barron2 and Daniel L. Kastner1, 1Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2Div Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anakinra, etanercept and fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS) is an autoinflammatory disease inherited in an autosomal dominant fashion.  TRAPS develops secondary to mutations in TNFRSF1A. Associated symptoms include periodic attacks of peritonitis, constipation, arthritis in large joints, arthralgia, migratory rash with underlying myalgia, periorbital edema, conjunctivitis, splenomegaly, and increased risk for AA amyloid deposition. Typically, attacks last from days to weeks. The common treatment modalities are corticosteroids, the p75:Fc fusion protein, etanercept, and IL-1 antagonists. Recent studies suggest that multiple cytokines are involved in the pathogenesis of TRAPS. To date, there are limited data comparing the efficacy of etanercept and IL-1 inhibitors in TRAPS. To explore this, we have analyzed the response of seven patients with TRAPS who were transitioned from etanercept to anakinra due to modest response while on etanercept.

Methods: CRP and ESR were measured serially in seven patients with TRAPS who had been initially treated with etanercept and were subsequently switched to anakinra. Patient records were evaluated for clinical and laboratory associations.  Patients with the R92Q and P46L variants were excluded from our analysis.

Results: Seven adult patients with TRAPS were switched from etanercept to anakinra therapy due to poor symptom control and persistent elevation in inflammatory markers. Among all seven patients, the range of ESR before starting anakinra (no patients were actively flaring at the time labs were drawn) was 37-91 mm/hr and after was 5-18 mm/hr. The range of CRP before starting anakinra was 18.10-186 mg/L and after was <0.5-8.85 mg/L. The etanercept doses ranged from 50mg weekly to 75mg weekly. The anakinra doses ranged from 100mg daily to 300mg daily. One patient with AA amyloidosis had normalization of proteinuria and stabilization of creatinine within 16 months of starting anakinra.  Patients reported fewer flares, shorter duration of flares, and decreased necessity for additional medications during flares (corticosteroids and narcotics).

Conclusion: Our findings indicate that in some patients, anakinra therapy is superior to etanercept therapy for TRAPS. Of the seven patients, all of them experienced clinically significant decreases in inflammatory markers including CRP and ESR as well as clinical improvement in symptoms related to TRAPS upon the initiation of anakinra.


Disclosure:

A. K. Ombrello,
None;

P. M. Hoffmann,
None;

A. Jones,
None;

K. Barron,
None;

D. L. Kastner,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-anakinra-therapy-in-seven-adults-after-suboptimal-response-to-etanercept-therapy-for-tumor-necrosis-factor-receptor-associated-periodic-fever-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology